Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NHS England has announced a programme to provide NHS staff with evidence-based digital programmes to protect their mental health during the COVID-19 response. The apps are designed to help maintain healthy sleep, and reduce anxiety.

Sleepio is an automated digital self-help app based on cognitive behavioural therapy for insomnia. It was built by Colin Espie, Professor of Sleep Medicine at the Nuffield Department of Clinical Neurosciences and Co-Founder of digital therapeutics company Big Health. Subsequent research by Espie and his team has demonstrated the efficacy and safety of Sleepio, and provided a platform for recognition of the value of digital therapeutics more widely in the NHS and other workplaces internationally.

Fifteen NHS trusts and six GP practices have already rolled out access to Sleepio and Daylight, an app designed to help with worry and anxiety. These apps have now been made freely available to all NHS employees across the country in partnership with NHS England.

Professor Colin Espie has praised NHS England’s quick response in protecting the mental health of NHS staff as well as their physical health during the pandemic. He said: ‘I’m honoured that Big Health is able to support our colleagues in the NHS to help safeguard their mental health during these most challenging of times. NHS staff are working under enormous pressure while also experiencing significant changes to their lives at home as a result of COVID-19.’

To learn how to gain access to Daylight and Sleepio for your staff, please email ceo@bighealth.com

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.